Nitrosamine Impurities in Dietary Supplements: What the Pharmaceutical Playbook Teaches Us

When FDA recalled ranitidine (Zantac) in April 2020, it wasn’t because the drug itself was poorly made. It was because the active ingredient degraded — under heat and moisture, over time — and generated N-nitrosodimethylamine, better known as NDMA. A probable human carcinogen. Present in millions of medicine cabinets across the country. The pharmaceutical industry reckoning that followed was sweeping: manufacturers retested hundreds of products, revised stability protocols, and invested heavily in analytical methods most of them hadn’t used before.

Dietary supplement manufacturers mostly watched from the sidelines.

That window is closing. FDA’s nitrosamine impurity framework, developed almost entirely in the drug context, is increasingly referenced by quality-conscious supplement brands, by retail compliance programs, and — pointedly — by legal teams who read the Zantac litigation outcomes carefully. If your supplement manufacturing program hasn’t seriously considered nitrosamine formation pathways, this piece is worth your time.

What Nitrosamines Are, and Why the Numbers Are So Small

Nitrosamines are a class of chemical compounds formed when secondary or tertiary amines react with nitrosating agents — nitrites, nitrogen oxides — under the right conditions of pH, temperature, and time. Most are classified as probable or possible human carcinogens by the International Agency for Research on Cancer (IARC). NDMA (Group 2A, “probably carcinogenic to humans”) is the most widely cited, but the family includes NDEA, NMBA, NMPA, NIPEA, NDIPA, and a growing list of compound-specific nitrosamines that FDA has identified in drug products since 2018.

The acceptable daily intake for NDMA, as established by FDA’s 2021 guidance on nitrosamine impurities in human drug products, is 96 nanograms per day. To put that in context: that’s roughly one ten-millionth of a gram. Detecting contamination at those levels requires LC-MS/MS or GC-MS/MS instrumentation — not the standard HPLC panels that catch most other impurities. Laboratories need validated methods with quantitation limits in the low nanogram-per-gram (ng/g) range for the result to be analytically meaningful.

For dietary supplements, FDA has not issued equivalent numerical limits. That’s the regulatory gap that currently defines this issue.

Where Nitrosamines Actually Form in Supplement Manufacturing

This is the part that matters most for a quality or operations team. Nitrosamine contamination in supplements doesn’t always arrive the way a heavy metal does — embedded in a botanical ingredient from contaminated agricultural soil. Nitrosamines are frequently generated, meaning they form during manufacturing, under storage conditions, or through equipment contact. Three pathways are especially relevant.

Formulation chemistry. Certain ingredients carry amine-containing molecular structures that can react with nitrosating agents under acidic or high-heat conditions. Choline, trimethylamine oxide, betaine, and various botanical alkaloids are worth scrutinizing at the formulation stage. If your formula contains a precursor amine and your manufacturing process involves elevated heat, pH adjustments, or prolonged blending, you have a potential formation pathway that deserves a risk assessment.

Manufacturing equipment contact surfaces. This one catches quality teams off guard more often than it should. Rubber gaskets, hoses, and tubing used in blending, encapsulation, and liquid filling equipment can leach nitrosamines directly into product — a mechanism FDA documented during several pharmaceutical investigations. The same risk applies in dietary supplement contract manufacturing facilities that haven’t audited their equipment material composition. Asking your CMO which contact surfaces are rubber-based, and whether those components have been screened for nitrosamine extractables and leachables, is a straightforward and entirely reasonable quality question.

Degradation during storage and distribution. Some nitrosamines don’t form until a product has been sitting at elevated temperature and humidity for months. This is a real limitation of point-in-time testing: a freshly manufactured batch might pass a nitrosamine screen at time zero but show meaningfully elevated levels at the 12-month or 24-month stability timepoint. Brands that perform nitrosamine screening only on release samples are getting an incomplete picture.

The Testing Gap — and the Forces Narrowing It

21 CFR Part 111, the current Good Manufacturing Practice regulation for dietary supplements, requires testing for identity, purity, strength, and composition — but doesn’t enumerate nitrosamine testing the way 21 CFR Part 211 does for finished pharmaceutical products. The ICH M7(R2) guideline, which governs assessment and control of mutagenic impurities (including nitrosamines) in drug products, has no dietary supplement equivalent.

But the gap is being filled from multiple directions simultaneously.

Amazon’s Supplement Quality and Compliance program, which governs listing eligibility for a large share of online supplement sales, has begun requesting risk assessment documentation that increasingly mirrors pharmaceutical quality practice. Major retailers — Whole Foods, CVS, Target — are asking similar questions through their supplier qualification programs. And California Proposition 65, independent of FDA, lists NDMA as a carcinogen with a no significant risk level (NSRL) of 96 ng/day. That limit is enforceable today, applies to any consumer product sold in California, and doesn’t wait for federal supplement-specific guidance to exist.

For brands that manufacture or sell in California — which covers a substantial share of the US direct-to-consumer supplement market — Prop 65 compliance for nitrosamines is an existing obligation, not a future one. Significant California sales exposure means this is already on the table whether or not a brand has noticed.

We’ve seen a meaningful increase in requests for nitrosamine risk assessments and targeted screening over the past 18 months. Most of those requests aren’t coming in response to a recall or a regulatory letter. They’re coming from brands whose retail partners or legal teams asked a question they couldn’t answer from their existing testing documentation.

Building a Practical Nitrosamine Testing Program for Supplements

A workable starting point has three components, and they don’t all require analytical testing.

Step 1: Risk assessment. Before ordering a single test, map your formulation for amine-containing raw materials and your manufacturing process for heat exposure, pH modification, and equipment contact surfaces. This is a desk exercise — a chemist reviewing spec sheets and a structured conversation with your contract manufacturer. The output should be a ranked list of which products in your portfolio carry meaningful nitrosamine formation risk. High-risk products get screened first; lower-risk products get screened on a rolling schedule.

Step 2: Targeted LC-MS/MS screening. For products that clear the risk assessment threshold, targeted screening for the seven nitrosamines FDA most commonly references — NDMA, NDEA, NMBA, NMPA, NIPEA, NDIPA, and MNP — provides a meaningful baseline. Turnaround from a qualified ISO 17025 accredited laboratory typically runs 10–15 business days for a validated method. Critically: ask the laboratory what their limit of quantitation (LOQ) is before submitting samples. Results are only useful if the method is sensitive enough to detect nitrosamines at the regulatory threshold levels. A screening panel that reports “not detected” against an LOQ of 500 ng/g tells you almost nothing useful.

Step 3: Stability-integrated monitoring. A clean time-zero result is informative but incomplete. Incorporating a nitrosamine check at the 6-month and 18-month real-time stability timepoints costs relatively little — typically $400–$800 per sample for a targeted panel — compared to the liability exposure of identifying a formation issue after a product has been on the market for two years.

Upstream Risk: Your Raw Material Suppliers

One dimension of nitrosamine risk that often doesn’t get discussed: the problem can start before materials arrive at your facility. Botanical extract suppliers, excipient manufacturers, and flavoring producers may be introducing amine precursors, nitrosating agents, or in some cases pre-formed nitrosamines in their raw materials. A certificate of analysis that doesn’t include nitrosamine-specific testing — with the method and LOQ clearly stated — doesn’t give you the information you need.

Supplier qualification programs that include nitrosamine screening of incoming raw materials are now part of what rigorous supplement quality programs look like. For ingredients with elevated risk profiles — choline-containing compounds, certain amino acid derivatives, herbal extracts with high alkaloid content — independent verification through your own contract testing laboratory provides assurance that COA review alone can’t.

Where the Regulatory Direction Is Heading

FDA hasn’t issued supplement-specific nitrosamine guidance, and based on current agency priorities, a formal supplement-focused document isn’t imminent. But the direction of travel is consistent and well-documented: impurity standards that originate in pharmaceutical regulation migrate to dietary supplements on a lag of roughly 3–7 years. Heavy metals followed that trajectory — USP 232/233 was developed for pharmaceutical applications and is now widely applied in supplement quality programs. Residual solvents followed the same arc. Nitrosamines are on the same path.

That lag isn’t a reason to wait. Brands that establish a nitrosamine testing baseline now will have longitudinal data, documented risk assessments, and supplier qualification records in place before any regulatory or retail requirement forces the issue. Brands that wait will be scrambling to produce documentation retroactively — which is a much harder position when you’re responding to a retailer audit or a regulatory inquiry.

The practical starting point is a risk assessment for your three highest-risk SKUs — the ones with complex formulations, amine-containing ingredients, or long shelf life targets. That exercise alone will tell you whether more targeted analytical work is warranted, and it produces documentation that demonstrates your quality program is thinking ahead of the compliance curve rather than behind it.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• FDA Regulatory Strategy for Supplement and Drug Manufacturers — Aurora TIC’s regulatory consultants help brands interpret evolving FDA impurity guidance and build compliant documentation packages.
• Raw Material Supplier Qualification and COA Verification — Ayah Labs provides independent raw material testing and supplier qualification support for global B2B ingredient buyers.
• Pharmaceutical Impurity Testing for Canadian Manufacturers — Androxa offers GMP-compliant impurity screening under Health Canada requirements for drug and supplement manufacturers.